Hemophilia & Von Willebrand Disease In Children: Factor 8, Factor 9, Factor VII, Factor IX, Clotting Factor Inhibitors, Factor Replacement Therapy | EB Medicine
0
TOC Will Appear Here

Hemophilia And Von Willebrand Disease In Children: Emergency Department Evaluation And Management

4,273 views
Below is a free preview. Log in or subscribe for full access. Or, get a free sample article ED Assessment and Management of Pediatric Acute Mild Traumatic Brain Injury and Concussion:
Please provide a valid email address.
Table of Contents
 
Table of Contents
  1. Abstract
  2. Case Presentations
  3. Introduction
  4. Critical Appraisal of the Literature
  5. Etiology And Pathophysiology
    1. Hemostasis And The Coagulation Cascade
    2. Pathophysiology Of Von Willebrand Disease
    3. Pathophysiology Of Hemophilia
  6. Differential Diagnosis
    1. Timing Of Diagnosis
    2. Typical Presenting Symptoms Of Inherited Bleeding Disorders At Diagnosis
      1. Hemarthrosis
      2. Hematomas/Soft-Tissue Bleeds
      3. Mucosal Bleeding
      4. Intracranial Hemorrhage
      5. Postsurgical Bleeding
  7. Prehospital Care
  8. Emergency Department Evaluation
  9. Diagnostic Studies
    1. Laboratory Studies
    2. Imaging Studies
      1. Head Imaging
      2. Joint And Soft-Tissue Imaging
  10. Treatment
    1. Treatment Of Bleeding From Hemophilia
  11. Special Populations
    1. Patients With Hemophilia With Inhibitors
      1. FEIBA Versus Recombinant Factor VIIa For Refractory Bleeding In Patients With Inhibitors
    2. Patients With Mild Hemophilia A: Treatment With Desmopressin
    3. Patients In Resource-Limited Settings
  12. Controversies And Cutting Edge
  13. Disposition
  14. Summary
  15. Risk Management Pitfalls In Hemophilia And Von Willebrand Disease In Children
  16. Time- And Cost-Effective Strategies
  17. Case Conclusions
  18. Acute Management Of Common Bleeds In Patients With Hemophilia
  19. Emergency Department Workup For Suspected Bleeding Disorder
  20. Tables
    1. Table 1. Differential Diagnosis For Bleeding Disorders By Abnormality In Prothrombin Time & Partial Thromoboplatin Time Studies
    2. Table 2. Summary Of The United Kingdom Haemophilia Centre Doctor's Organisation Evaluation Guidelines
    3. Table 3. Available Factor Replacement Products
    4. Table 4. Dosing And Duration Of Therapy For Hemophilia-Related Bleeds
    5. Table 5. Dosing Of Von Willebrand Factor Concentrates For Major And Minor Bleeding And Surgery
  21. References

Abstract

Hemophilia and von Willebrand disease are the most common inherited bleeding disorders encountered in the emergency department. Evidence suggests that the management of bleeding disorders in the emergency department is currently suboptimal, and literature to guide evaluation and management in this setting is limited, though some guidelines do exist. The emergency clinician must have a high index of suspicion for new diagnoses, particularly in young patients with unprovoked bleeding and children with multiple or severe bleeds. The foundation of hemophilia treatment is urgent clotting factor replacement, with replacement goals guided by the presenting complaint. Bleeding in von Willebrand disease may be treated with products containing von Willebrand factor or with desmopressin. This review focuses on the epidemiology, pathophysiology, common presentations, evaluation strategies, and emergency management of these bleeding disorders.

Case Presentations

A 7-year-old boy with a history of severe hemophilia B, who receives scheduled prophylactic factor IX 3 times a week, presents to the emergency department after rolling off a bed 3 feet from the ground and striking his head. He complains of a mild headache at this time. On examination, there is no palpable scalp hematoma, and the neurologic examination is entirely normal. The patient’s last prophylactic factor infusion was 2 days ago. Given his normal examination at this time, is head imaging indicated? Should he receive a factor IX infusion? If so, when should it be administered, and how much should be given? The patient uses AlphaNine® SD brand factor IX for his factor replacement at home, but your emergency department only stocks BeneFIX® brand factor IX. Is it okay to switch factor products? Are there risks to doing so?

A 17-year-old adolescent boy with a history of severe hemophilia A with a high-titer inhibitor presents to the emergency department with pain and swelling in his right knee that developed at school that day. There is no history of antecedent trauma. Examination of the affected knee reveals a large effusion and pain with flexion > 90°. Are there laboratory studies or imaging that could aid in diagnostic decision-making? Should you perform arthrocentesis either diagnostically or therapeutically? Should you treat with a factor VIII concentrate? How does the presence of a high-titer inhibitor change your management? Your ED stocks both FEIBA and recombinant factor VIIa as bypassing products. Is one better than the other for this patient? Can this patient be discharged from the emergency department after treatment or does the presence of inhibitors preclude home management?

A 16-year-old girl presents to the emergency de-partment with a 1-month history of menorrhagia. Her primary care physician has seen her for this complaint previously and has sent laboratory tests, including a complete blood count and prothrombin time/partial thromboplastin time, which were normal. Her von Willebrand panel was significant for a low von Willebrand factor antigen level (vWF:Ag) of 20 IU/dL and a low ristocetin cofactor activity level (vWF:RCo) of 22 IU/dL. She has not started any treatment. What is her likely diagnosis, and what treatment options are available for this patient to decrease menorrhagia? Should she receive oral contraceptive pills, desmopressin, and/or aminocaproic acid? What risks are associated with these therapies? Should her family members seek testing for bleeding disorders?

Introduction

Hemophilia and von Willebrand disease (vWD) represent the most common inherited bleeding disorders, and, consequently, those most likely to be encountered in the emergency department (ED).1 Hemophilia A and B are X-linked recessive disorders caused by the deficiency or absence of coagulation factors VIII and IX, respectively. The overall incidence of hemophilia is 1 per 5000 male births. Hemophilia A is significantly more common than hemophilia B, representing 80% of all hemophilia cases.2 Significant and often life-threatening bleeding (either spontaneous or trauma-induced) is the hallmark of this disease.3 Historically, hemophilia was associated with a dismal prognosis, with most patients dying at a young age of uncontrolled hem-orrhage.3 However, life expectancy has increased dramatically in the past 50 years with the advent of plasma-derived and recombinant clotting factor concentrates for treatment of hemophilia. Life expectancy for hemophilia patients in developed countries with comprehensive longitudinal care now approaches that of the general male population.4,5

Von Willebrand disease is significantly more common than hemophilia; however, bleeding in vWD is generally much less severe than that seen in hemophilia. Epistaxis, menorrhagia, oral bleeding, easy bruising, and greater-than-expected postsurgical bleeding are typical presentations of vWD compared to hemophilia, in which more-severe joint, intracranial, and intramuscular hemorrhages are observed.6 Unlike hemophilia, vWD affects men and women equally, with a prevalence as high as 1% of the population, although significantly fewer people will be symptomatic from the disease.7 Von Willebrand disease is not an X-linked disorder, and multiple genetic inheritance patterns exist. Among these, autosomal dominant is the most common pattern. Von Willebrand disease is caused by quantitative or qualitative deficiencies in von Willebrand factor (vWF), a glycoprotein important for platelet aggregation and adhesion to sites of vessel injury.8

Together, vWD and hemophilia A and B represent the vast majority of clinically significant inherited bleeding disorders. Other inherited bleeding disorders do exist and include functional or quantitative deficiencies in clotting factors II, V, VII, X, XI, and XIII, as well as fibrinogen deficiencies. However, these deficiencies, collectively known as the rare bleeding disorders, represent only 3% of all bleeding disorders and each occur with a prevalence of 1 in 500,000.9 Therefore, they will not be addressed in detail within this review. Acquired bleeding disorders also will not be reviewed here.

In patients diagnosed with hemophilia, ED visits are frequent. Not surprisingly, the majority of these visits are for acute bleeding, where prompt and appropriate intervention by an emergency clinician is critical in mitigating morbidity and mortality.10,11 In some cases, a new diagnosis of a bleeding disorder may be first identified in the ED.11,12 However, several lines of evidence indicate that many emergency clinicians have little experience and lack familiarity in evaluating and managing patients with the common inherited bleeding disorders.1,10 Expert guidelines for the evaluation and management of patients with inherited bleeding disorders exist,13-15 but such recommended standards are often not met in the ED care of patients with hemophilia.16 Thus, evidence-based knowledge of ED evaluation and management of inherited bleeding disorders is critical.

Critical Appraisal Of The Literature

A literature search was performed in PubMed using the search terms hemophilia, factor VIII deficiency, factor IX deficiency, Christmas disease, children, and pediatric. This search yielded 5999 results that were evaluated by the authors, with 118 papers deemed relevant to this review of hemophilia A and B. A separate search was conducted using the search terms von Willebrand disease, children, and pediatric. This search yielded 1132 results which were reviewed, identifying 30 relevant references for vWD. The Cochrane Database of Systematic Reviews was searched using the key terms hemophilia and von Willebrand disease. This search yielded 12 results, 3 of which were relevant to this ED-focused review.

A search of The National Guideline Clearinghouse (www.guideline.gov) yielded 2 sets of guidelines for hemophilia from the World Federation of Hemophilia and the British Committee for Standards in Haematology, and 1 guideline for vWD from the National Heart, Lung, and Blood Institute of the National Institutes of Health. Most recommendations regarding acute treatment of inherited bleeding disorders contained within the hemophilia guidelines are level IV (based on case series/historically controlled studies), with the exception of recommendations for factor prophylaxis, which have stronger evidence (level II, based on randomized controlled trials). For vWD, recommendations are largely derived from case series and retrospective reports (almost all grade C recommendations with level IV evidence).

The absence of a significant number of large randomized trials for hemophilia is multifactorial. Modern hemophilia care began with the development of plasma-derived factor concentrates in the 1960s. Subsequent research was confounded by the staggering number of patients with hemophilia who were affected by HIV infections contracted via plasma-derived clotting factor infusions in the late 1970s and early 1980s.17 A 1998 study by Rosenberg and Goedert estimated that nearly half of all patients with hemophilia living in the United States were infected with HIV.18 Despite being the most common inherited clotting factor deficiency, hemophilia remains a rare disease, and randomized controlled trials generally require multicenter participation to accrue an adequate number of patients. Modern national registries for patients with hemophilia have aided in consolidating retrospective information on these patients, but they have not effectively facilitated a large number of prospective multicenter trials.19

Defining vWD has been challenging for the purpose of creating cohorts of subjects.7 Many patients with abnormal testing on von Willebrand laboratory panels have no clinical manifestations of bleeding, and, yet, some patients with equivocal testing on von Willebrand panels are significantly symptomatic.8 These complications have made accurate identification of a study population more challenging. Because of the rational basis for giving factor concentrates in cases of acute bleeding in pediatric patients, the relatively low risk of doing so in the era of recombinant factor concentrates, and excellent infection screening for plasma-derived products, a randomized trial withholding factor concentrates for patients with acute bleeds is not feasible, nor is it appropriate.

Risk Management Pitfalls In Hemophilia And Von Willebrand Disease In Children

  1. “I wanted to confirm on imaging that an intracranial bleed was actually present before I infused factor.”
    Factor should be administered immediately upon suspicion of intracranial hemorrhage. Delay in factor administration has the potential to increase morbidity and mortality, and the risk of factor administration is minimal. When in doubt, infuse factor.
  2. “This patient had a high-titer inhibitor, so I gave higher doses of factor to overcome the inhibitor to try to stop the bleeding.”
    High-titer inhibitors (> 5 BU/mL) cannot be overcome with higher doses of factor concentrates. A bypassing agent (FEIBA or rFVIIa) is required to treat bleeding in these patients.
  3. “This patient with severe hemophilia only had minimal head trauma and has a normal examination. He can’t have a significant ICH.”
    Most patients with hemophilia with ICH report only minor trauma history, and many will have a completely normal physical examination.
  4. “This infant has no family history of hemophilia, so he can’t have hemophilia.”
    Thirty percent of cases of hemophilia are new mutations without any family history. Maintain a high index of suspicion for hemophilia in a male patient with significant bleeding, and maintain a low threshold for screening PT/PTT.
  5. “We don’t have any factor VIII concentrates available here. There is nothing I can do for this patient with hemophilia A and worsening hemarthrosis.”
    In settings where factor VIII concentrate is unavailable, cryoprecipitate (which contains high levels of factor VIII) may be used at a dose of 1 bag/6 kg body weight, to a max of 10 bags, initially to treat acute bleeding.
  6. “This patient’s factor VIII level is low. He must have hemophilia A.”
    This is likely the case, but he may also have type 2N or type 3 vWD. Distinguishing between these diseases will help guide factor replacement, and a von Willebrand panel should be sent.
  7. “This patient with hemophilia did not bring his factor concentrate with him to the ED, and we don’t stock his brand of concentrate here, so we should wait until his factor arrives from home to treat his hemarthrosis.”
    There is no clear evidence that switching between factor brands increases the risk of inhibitor development. Depending on the severity of the bleed and the anticipated delay in acquiring the patient’s home product, administration of another brand of product may be appropriate. However, recombinant products are preferred, rather than switching from a recombinant product to a plasma-derived product.
  8. “This patient with vWD needs emergent surgery. We can just give desmopressin preoperatively, and that should be fine.”
    This may be true; however, a documented response to desmopressin with an appropriate increase in vWF is necessary before relying on this therapy. If the patient has not been shown to be responsive to desmopressin (either has not had a test confirming desmopressin response or has had a test which showed nonresponsiveness to desmopressin), a factor product containing large concentrations of vWF is indicated rather than using desmopressin.
  9. “My patient with hemophilia is complaining of numbness along the lateral thigh and is having trouble extending his right leg. We should get a neurology consultation and head imaging, as this may be a stroke.”
    These are typical presenting signs of an iliopsoas hemorrhage. Treatment should be centered on factor replacement to 80%, and imaging should be directed at the psoas region by CT, MRI, or ultrasound. Significant blood loss in this area is possible, and transfusion may be required.
  10. “This patient has menorrhagia and easy bruising, and her mother and sister have a history of similar symptoms. She already had a normal von Willebrand panel test, so she can’t have vWD.”
    Many factors affect measured vWF levels, including stress, illness, exercise, reproductive hormone levels, and specimen storage and transport. False negatives are common, and a single negative test does not rule out the disease, especially in patients with signs and symptoms suggestive of the disease.

Tables

Table 1. Differential Diagnosis For Bleeding Disorders By Abnormality In Prothrombin Time & Partial Thromoboplatin Time Studies

References

Evidence-based medicine requires a critical appraisal of the literature based upon study methodology and number of subjects. Not all references are equally robust. The findings of a large, prospective, randomized, and blinded trial should carry more weight than a case report.

To help the reader judge the strength of each reference, pertinent information about the study, such as the type of study and the number of patients in the study will be included in bold type following the references, where available. The most informative references cited in this paper, as determined by the author, will be noted by an asterisk (*) next to the number of the reference.

  1. * Singleton T, Kruse-Jarres R, Leissinger C. Emergency department care for patients with hemophilia and von Willebrand disease. J Emerg Med. 2010;39(2):158-165. (Review)
  2. * Josephson N. The hemophilias and their clinical management. Hematology Am Soc Hematol Educ Program. 2013;2013:261-267. (Review)
  3. Di Michele D, Neufeld EJ. Hemophilia: a new approach to an old disease. Hematol Oncol Clin North Am. 1998;12(6):1315- 1344. (Review)
  4. Mannucci PM, Mancuso ME, Santagostino E. How we choose factor VIII to treat hemophilia. Blood. 2012;119(18):4108-4114. (Review)
  5. Lovdahl S, Henriksson KM, Baghaei F, et al. Incidence, mortality rates and causes of deaths in haemophilia patients in Sweden. Haemophilia. 2013;19(3):362-369. (Retrospective cohort study; 1431 cases and 7150 controls)
  6. * Rodeghiero F, Castaman G, Tosetto A. How I treat von Willebrand disease. Blood. 2009;114(6):1158-1165. (Expert opinion with literature review)
  7. * Yawn B, Nichols WL, Rick, ME. Diagnosis and management of von Willebrand disease: guidelines for primary care. Am Fam Phys. 2009;80(11):1261-1268. (Expert consensus guidelines)
  8. * Mannucci PM. Treatment of von Willebrand’s disease. N Engl J Med. 2004;351(7):683-694. (Review)
  9. Acharya SS. Rare bleeding disorders in children: identification and primary care management. Pediatrics. 2013;132(5):882-892. (Review)
  10. Nuss R, Hoffman R, Hammond L. ED Visits by males with hemophilia. Am J Emerg Med. 2002;20(2):74-78. (Medical record review; 51 patients)
  11. Ozgonenel B, Zia A, Callaghan MU, et al. Emergency department visits in children with hemophilia. Pediatr Blood Cancer. 2013;60(7):1188-1191. (Medical record review; 536 emergency department visits, 84 male patients)
  12. Minhas HL, Giangrande PL. Presentation of severe haemophilia--a role for accident and emergency doctors? Emerg Med J. 2001;18(4):246-249. (Questionnaire and survey; 25 patients)
  13. Richards M, Williams M, Chalmers E, et al. A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol. 2010;149(4):498-507. (Practice guidelines)
  14. * Treatment Guidelines Working Group. Guidelines for the management of hemophilia. 2nd ed. Montreal, Quebec: World Federation of Hemophilia. 2012. (Consensus guidelines)
  15. * Nichols WL, Hultin, MB, James AH, et al. The diagnosis, evaluation and management of von Willebrand disease. National Heart Lung and Blood Institute. NIH Publication No. 08-5832. Bethesda, MD; 2012. (Practice guidelines)
  16. * Fowler H, Lacey R, Keaney J, et al. Emergency and out of hours care of patients with inherited bleeding disorders. Haemophilia. 2012;18(3):e126-e131. (Practice guidelines audit)
  17. Key NS, Negrier C. Coagulation factor concentrates: past, present and future. Lancet. 2007;370(9585):439-448. (Review)
  18. Rosenberg PS, Goedert JJ. Estimating the cumulative incidence of HIV infection among persons with haemophilia in the United States of America. Stat Med. 1998;17(2):155-168. (Multicenter data analysis)
  19. Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007;110(3):815-825. (Retrospective review; 6018 cases)
  20. Kumar R, Carcao. Inherited abnormalities of coagulation: hemophilia, von Willebrand disease, and beyond. Pediatr Clin North Am. 2013;60(6):1419-1441. (Review)
  21. Robertson J, Lillicrap D, James PD. von Willebrand disease. Pediatr Clin North Am. 2008;55(2):377-392. (Review)
  22. Mortimore W. Focus on diagnosis: screening for von Willebrand disease. Pediatr Rev. 2005;26(302):301-303. (Expert opinion and review)
  23. Zimmerman B, Valentino LA. Hemophilia: in review. Pediatr Rev. 2013;34(7):289-295. (Review)
  24. Di Michele DM, Gibb C, Lefkowitz JM, et al. Severe and moderate haemophilia A and B in US females. Haemophilia. 2014;20(2):e136-e143. (Multicenter retrospective study; 22 patients)
  25. Sharathkumar A, Pipe S. Bleeding disorders. Pediatr Rev. 2008;29(4):121-130. (Review)
  26. Pollmann H, Richter H, Ringkamp H, et al. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr. 1999;158 Suppl 3:S166-S170. (Prospective single-center study; 37 patients)
  27. Venkateswaran L, Wilimas JA, Jones DJ, et al. Mild hemophilia in children: prevalence, complications and treatment. J Pediatr Hematol Oncol. 1998;20(1):32-35. (Retrospective chart review; 55 patients)
  28. Berntorp E, Halimeh S, Gringeri A, et al. Management of bleeding disorders in children. Haemophilia. 2012;18 Suppl 2:15-23. (Review)
  29. Nolan B, Vidler V, Vora A, et al. Unsuspected haemophilia in children with a single swollen joint. BMJ. 2003;326(7381):151- 152. (Case reports; 2 patients)
  30. Beyer R, Ingersley J, Sorensen B. Muscle bleeds in professional athletes - diagnosis, classification, treatment and potential impact in patients with haemophilia. Haemophilia. 2010;16(6):858-865. (Review paper)
  31. Plummer ES, Crary SE, Buchanan GR. Prominent forehead hematomas (“goose-eggs”) as an initial manifestation of hemophilia. J Pediatr. 2013;163(6):1781-1783. (Retrospective chart review; 324 patients)
  32. Teitel J, Berntorp E, Collins P, et al. A systematic approach to controlling problem bleeds in patients with severe congenital hemophilia A and high-titre inhibitors. Haemophilia. 2007;13(3):256-263. (Expert panel consensus guidelines)
  33. Witmer C, Presley R, Kulkarni J, et al. Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. Br J Haematol. 2010;152(2):211-216. (Case-control study; 199 patients)
  34. Labarque V, Stain AM, Blanchette V, et al. Intracranial haemorrhage in von Willebrand disease: a report on six cases. Heamophilia. 2013;19(4):602-606. (Retrospective chart review; 24 patients)
  35. Antunes SV, Vicari P, Cavalheiro S, et al. Intracranial haemorrhage among a population of haemophilic patients in Brazil. Haemophilia. 2003;9(5):573-577. (Retrospective cohort study; 401 patients, 45 with intracranial hemorrhage)
  36. Sun GH, Aauger KA, Aliu O, et al. Posttonsillectomy hemorrhage in children with von Willebrand disease in hemophilia. JAMA Otolaryngol Head Neck Surg. 2013;139(3):245-249. (Retrospective chart review; 508 patients)
  37. Kavakli K, Yesilipek A, Antmen B, et al. The value of early treatment in patients with haemophilia and inhibitors. Haemophilia. 2010;16(3):487-494. (Retrospective cohort study; 129 bleeding episodes)
  38. Sørensen B, Dargaud Y, Kenet G, et al. On-demand treatment of bleeds in haemophilia patients with inhibitors; strategies for securing and maintaining predictable efficacy with recombinant activated factor VII. Haemophilia. 2012;18(2):255- 262. (Expert consensus recommendations)
  39. Blankenship CS, Tortella BJ, Bruno, M. BE EMPOWERED, a specialty pharmacy education program for hemophilia B patients, impacts adult joint bleeds and pediatric use of RICE. J Manag Care Pharm. 2014;20(2):151-158. (Prospective cohort study; 21 subjects)
  40. Gill JC. Therapy of factor VIII deficiency. Semin Thromb Hemost. 1993;19(1):1-12. (Review)
  41. Nagel K, Pai MK, Paes BA, et al. Diagnosis and treatment of intracranial hemorrhage in children with hemophilia. Blood Coagul Fibrinolysis. 2013;24(1):23-27. (Review)
  42. Witmer CM, Raffini LJ, Manno CS. Utility of computed tomography of the head following head trauma in boys wth haemophilia. Haemophilia. 2007;13(5):560-566. (Review)
  43. Traivaree C, Blanchette V, Armstrong G, et al. Intracranial bleeding in haemophilia beyond the neonatal period - the role of CT imaging in suspected intracranial bleeding. Haemophilia. 2007;13(5):552-559. (Retrospective chart review; 43 patients)
  44. Hermans C, De Moerloose P, Fisher K, et al. Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations. Haemophilia. 2011;17(3):383-392. (Review)
  45. Melchiorre D, Linari S, Innocenti M, et al. Ultrasound detects joint damage and bleeding in haemophilic arthropathy: a proposal of a score. Haemophilia. 2011;17(1):112-117. (Prospective cohort study; 83 joint bleeds)
  46. Sorensen B, Benson GM, Bladen M, et al. Management of muscle haematomas in patients with severe haemophilia in an evidence poor world. Haemophilia. 2012;18(4):598-606. (Review)
  47. Matysiak M, Bobrowska H, Balwierz W, et al. Clinical experience with Optivate®, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia A. Haemophilia. 2011;17(5):737-742. (Prospective cohort study; 25 children)
  48. Pollmann H, Externest D, Ganser A, et al. Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria. Haemophilia. 2007;13(2):131-143. (Postmarketing surveillance study, 217 patients)
  49. Scharrar I, Ehrlich HJ. Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII. Haemophilia. 2001;7(4):346-348. (Review)
  50. Rubinger M, Lillicrap D, Rivard GE, et al. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia. 2008;14(2):281-286. (Retrospective cohort study)
  51. Mannucci PM. Treatment of haemophilia: building on strength in the third millenium. Haemophilia. 2011;17(Suppl 3):1-24. (Review)
  52. Branchford BR, Monahan PE, Di Paola J. New developments in the treatment of pediatric hemophilia and bleeding disorders. Curr Opin Pediatr. 2013;25(1):23-30. (Review)
  53. Nguyen DD, Takenaka K. Evaluation and management of hereditary hemophilia in the emergency department. J Emerg Nurs. 2009;35(5):437-441. (Review)
  54. Alexander M, Barnes C, Barnett P. Prospective audit of patients with haemophilia: Bleeding episodes and management. J Pediatr and Child Health. 2012;48(2):177-179. (Prospective cohort study; 66 children)
  55. Petrini P. Treatment strategies in children with hemophilia. Pediatr Drugs. 2002;4(7):427-437. (Review)
  56. Kisker CT, Burke C. Double-blind studies on the use of steroids in the treatment of acute hemarthrosis in patients with hemophilia N Engl J Med. 1970;282(12):639-642. (Review)
  57. Rodriguez-Merchan E. Acute compartment syndrome in haemophilia. Blood Coagul Fibrinolysis. 2013;24(7):677-682. (Systematic review; 34 patients)
  58. Ashrani AA, Osip J, Christie B, et al. Iliopsoas haemorrhage in patients with bleeding disorders--experience from one centre. Haemophilia. 2003;9(6):721-726. (Retrospective review; 297 patients)
  59. Balkan C, Kavakli K, Karapinar D. Iliopsoas haemorrhage in patients with haemophilia: results from one centre. Haemophilia. 2005;11(5):463-467. (Chart review; 146 patients)
  60. Fernandez-Palazzi F, Hernandez SR, De Bosch NB, et al. Hematomas within the iliopsoas muscles in hemophilic patients: the Latin American experience. Clin Orthop. 1996;328:19-24. (Retrospective cohort study)
  61. Revel-Vilk S, Golomb MR, Achonu C, et al. Effect of intracranial bleeds on the health and quality of life of boys with hemophilia. J Pediatr. 2004;144(4):490-495. (Case-control study; 172 patients, 18 with intracranial hemorrhage)
  62. Klinge J, Auberger K, Auerswald G, et al. Prevalence and outcome of intracranial haemorrhage in haemophiliacs - a survey of the paediatric group of the German Society of Thrombosis and Haemostasis (GTH). Eur J Pediatr. 1999;158(Suppl 3):S162-S165. (Retrospectve cohort study; 744 patients, 30 intracranial hemorrhages)
  63. Andes WA, Wulff K, Smith WB. Head trauma in hemophilia. A prospective study. Arch Intern Med. 1984;144(10):1981-1983. (Prospective study; 140 patients)
  64. Malec LM, Sidonio RF Jr, Smith KJ, et al. Three cost-utility analyses of screening for intracranial hemorrhage in neonates with hemophilia. J Pediatr Hematol Oncol. 2014;36(6):474-479. (Cost-utility analysis)
  65. Iorio A, Marchesini E, Marcucci M, et al. Clotting factor concentrates given to prevent bleeding and bleeding related complications in people with hemophilia A. Cochrane Database Syst Rev. 2011;9:CD003429. (Systematic review)
  66. Manco-Johnson MJ, Abshire TC, Shaprio AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535- 544. (Randomized controlled trial; 65 patients)
  67. Nagel K, Walker I, Decker K, et al. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients. Haemophilia. 2011;17(6):872-874. (Data analysis; 78 patients)
  68. Pasi KJ. Haemophila and adolescence. Haemophilia. 2011;17(Suppl. 3):1-24. (Review)
  69. Khair K, Baker K, Mathias M, et al. Intranasal desmopressin (Octim): a safe and efficacious treatment option for children with bleeding disorders. Haemophilia. 2007;13(5):548-551. (Prospective noncontrolled single-arm medication trial; 20 children)
  70. Di Michele D. Inhibitor treatment in haemophilias A and B: inhibitor diagnosis. Haemophilia. 2006;12(Suppl 6):37-42. (Review)
  71. Oren H, Yaprak I, Irken G. Factor VIII inhibitors in patients with hemophilia A. Acta Haematologica. 1999;102(1):42-46. (Retrospectve chart review; 58 patients)
  72. Hay CR, Palmer B, Chalmers E, et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood. 2011;117(23):6367-6370. (Database review; 2528 patients)
  73. Kempton CL, White GC. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood. 2009;113(1):11-17. (Review)
  74. Collins PW, Chalmers E, UK Hemophilia Centre Doctors, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol. 2013;160(2):153- 170. (Practice guidelines)
  75. Pan-Petesch B, Laguna P, Mital A, et al. Single-dose (270 ug/ kg) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhbitors: experience from seven European haemophila centers. Haemophilia. 2009;15(3):760-765. (Retrospective study and expert recommendation; 8 patients)
  76. Santagostino E, Mancuso ME, Rocino A, et al. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemo-philiacs with inhibitors. J Thromb Haemost. 2006;4(2):367-371. (Randomized trial; 20 patients)
  77. Laguna P, Mital A. Single higher dose of recombinant activated factor VII in the treatment of hemorrhages in patients with hemophilia complicated by inhibitors. Adv Clin Exp Med. 2012;21(4):519-524. (Prospective trial; 7 patients)
  78. Parameswaran R, Shapiro AD, HTRS Registry Investigators, et al. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhbitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia. 2005;11(2):100-106. (Retrospective chart review; 38 patients, 555 bleeding episodes)
  79. Young G, Shapiro AD, Walsh CE, et al. Patient/caregiver-reported recombinant factor VIIa(rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE). Haemophilia. 2012;18(3):392-399. (Prospective observational study; 158 bleeding episodes)
  80. Holme PA, Glomstein A, Grønhaug S, et al. Home treatment with bypassing products in inhitor patients: a 7.5 year experience. Haemophilia. 2009;15(3):727-732. (Prospective observational study; 10 patients)
  81. O’Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295(2):293-298. (Database review; 431 adverse event reports)
  82. Neufeld EJ, Saxena K, Kessler CM, et al. Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: the experience of the Hemostasis and Thrombosis Research Society (HTRS) Registry (2004-2008). Pediatr Blood Cancer. 2013;60:1178-1183. (Retrospective database review; 284 children with 1712 episodes, 146 adults with 329 episodes)
  83. Konkle BA, Ebbeson LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007;5(9):1904-1913. (Randomized prospective trial; 38 patients)
  84. Astermark J, Donfield, SM, Di Michele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109(2):546-551. (Randomized trial; 96 bleeding episodes in 48 patients)
  85. Gringeri A, Fischer K, Karafoulidou A, et al. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia. 2011;17(4):630-635. (Retrospective database review; 11 patients)
  86. Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia. 2004;10(4):347-351. (Retrospective chart review; 20 patients)
  87. Gill JC, Ottum M, Schwartz B. Evaluation of high concentration intranasal and intravenous desmopressin in pediatric patients with mild hemophilia A or mild-to-moderate type 1 von Willedbrand disease. J Pediatr. 2002;140(5):595-599. (Open-label single-dose trial; 25 patients)
  88. Santagostino E. Managing mild haemophila A. Haemophilia. 2011;17(Suppl. 3):21-24. (Review)
  89. Revel-Vilk S, Blanchette VS, Sparling C, et al. DDAVP challenge tests in boys with mild/moderate haemophilia A. Br J Haematol. 2001;117(4):947-951. (Retrospective chart review; 62 patients)
  90. Ehl S, Severin T, Sutor AH. DDAVP (desmopressin; 1-deamino-cys-8-D-arginine-vasopressin) treatment in children with hemophilia B. Br J Haematol. 2000;111(4):1260-1262. (Prospective trial; 4 patients.)
  91. Chuansumrit A. Treatment of haemophilia in the developing countries. Haemophilia. 2003;9(4):387-390. (Review)
  92. De Kleijn P, Odent T, Berntorp E, et al. Differences between developed and developing countries in paediatric care in haemophilia. Haemophilia. 2012;18 Suppl 4:94-100. (Review)
  93. Treatment Guidelines Working Group. Guidelines for the management of hemophilia. Montreal, Quebec: World Federation of Hemophilia. 2005. (Consensus guidelines)
  94. Zhou ZY, Koerper MA, Johnson KA, et al. Burden of illness: direct and indirect costs among persons with hemophilia A in the United States. J Med Econ. 2015;18(6):457-465. (Multicenter retrospective review and data analysis; 222 patients)
  95. Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369(24):2313-2323. (Phase 3 nonrandomized open-label study; 123 patients)
  96. Sharma A, Easow Mathew M, Sriganesh V, et al. Gene therapy for haemophilia. Cochrane Database Syst Rev. 2014;11:CD010822. (Systematic review)
  97. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357-2365. (Prospective cohort study; 6 participants)
Already purchased this course?
Log in to read.
Purchase a subscription

Price: $449/year

140+ Credits!

Money-back Guarantee
Publication Information
Authors

Kevin R. Schwartz, MD; Max Rubinstein, MD

Publication Date

September 2, 2015

Get Permission

Content You Might Be Interested In

Intracerebral Hemorrhage In Anticoagulated Patients: Evidence-Based Emergency Department Management (Stroke CME)

Emergency Department Evaluation And Management Of Patients With Upper Gastrointestinal Bleeding

Get A Sample Issue Of Emergency Medicine Practice
Enter your email to get your copy today! Plus receive updates on EB Medicine every month.
Please provide a valid email address.